Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies [Yahoo! Finance]
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its price target raised by analysts at Chardan Capital from $31.00 to $42.00. They now have a "buy" rating on the stock.